---
title: Diphtheria Toxoid + Meningococcal Vaccine
description: >-
  Diphtheria Toxoid + Meningococcal Vaccine is prescribed for active
  immunization against invasive meningococcal disease caused by *Neisseria
  meningitidis* serogroups A, C, Y, and W-135.  It also provides protection
  against diphtheria.  This combined vaccine falls under the pharmacological
  classifi...
is_banned: false
lastModified: '2025-09-22T17:22:09.099Z'
faqs:
  - q: >-
      What is the recommended dosage for Diphtheria Toxoid + Meningococcal
      Vaccine?**


      **A:**  See dosage section for details, which vary by age and specific
      vaccine product.
    a: >-
      A:**  See dosage section for details, which vary by age and specific
      vaccine product.
  - q: >-
      Can this vaccine be given to immunocompromised patients?**


      **A:** Yes, but the immune response might be suboptimal, and additional
      doses or alternative strategies may be necessary.
    a: >-
      A:** Yes, but the immune response might be suboptimal, and additional
      doses or alternative strategies may be necessary.
  - q: >-
      Does this vaccine protect against all types of meningitis?**


      **A:** No, it targets specific *N. meningitidis* serogroups (A, C, Y,
      W-135) and diphtheria, not other causes of meningitis (e.g., serogroup B,
      viral meningitis).
    a: >-
      A:** No, it targets specific *N. meningitidis* serogroups (A, C, Y, W-135)
      and diphtheria, not other causes of meningitis (e.g., serogroup B, viral
      meningitis).
  - q: >-
      What are the most common side effects?**


      **A:** The most common side effects are injection site reactions (pain,
      redness, swelling), headache, fatigue, and low-grade fever.
    a: >-
      A:** The most common side effects are injection site reactions (pain,
      redness, swelling), headache, fatigue, and low-grade fever.
  - q: >-
      Are there any contraindications to this vaccine?**


      **A:** A history of severe allergic reaction to any vaccine component,
      including diphtheria toxoid, is a contraindication.
    a: >-
      A:** A history of severe allergic reaction to any vaccine component,
      including diphtheria toxoid, is a contraindication.
  - q: >-
      Can this vaccine be administered during pregnancy or breastfeeding?**


      **A:**  Safety during pregnancy and breastfeeding has not been fully
      established. Administer only if benefits clearly outweigh potential risks
      and discuss all options with the patient.
    a: >-
      A:**  Safety during pregnancy and breastfeeding has not been fully
      established. Administer only if benefits clearly outweigh potential risks
      and discuss all options with the patient.
  - q: >-
      Can this vaccine be given with other vaccines?**


      **A:** Yes, but concurrent administration with certain vaccines may alter
      the immune response. Consult relevant guidelines and package inserts for
      specific recommendations.
    a: >-
      A:** Yes, but concurrent administration with certain vaccines may alter
      the immune response. Consult relevant guidelines and package inserts for
      specific recommendations.
  - q: >-
      What should be done if a patient experiences a mild allergic reaction
      after vaccination?**


      **A:**  Mild reactions (e.g., localized hives) can often be managed with
      antihistamines. Observe the patient and provide appropriate medical care
      as needed.
    a: >-
      A:**  Mild reactions (e.g., localized hives) can often be managed with
      antihistamines. Observe the patient and provide appropriate medical care
      as needed.
  - q: >-
      How long does immunity last after vaccination?**


      **A:**  Immunity wanes over time.  Booster doses are recommended for
      individuals at continued risk, generally after several years.
    a: >-
      A:**  Immunity wanes over time.  Booster doses are recommended for
      individuals at continued risk, generally after several years.
  - q: >-
      Is a prior history of GBS a contraindication to this vaccine?**


      **A:**  While GBS has been reported following meningococcal vaccination,
      it is not considered an absolute contraindication. Assess the individual
      patient's risk-benefit ratio.
    a: >-
      A:**  While GBS has been reported following meningococcal vaccination, it
      is not considered an absolute contraindication. Assess the individual
      patient's risk-benefit ratio.
---
## **Usage**

Diphtheria Toxoid + Meningococcal Vaccine is prescribed for active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135.  It also provides protection against diphtheria.  This combined vaccine falls under the pharmacological classification of **vaccines**, specifically **bacterial vaccines** and **toxoids**.  It works by stimulating the immune system to produce antibodies against these pathogens, preventing infection.

## **Alternate Names**

The generic name is Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine.  Brand names include Menactra®, Menveo®, and Nimenrix®.  Other names may include  "meningitis vaccine", "MenACWY vaccine", or quadrivalent meningococcal conjugate vaccine (4vMenCV).


## **How It Works**

**Pharmacodynamics:** The vaccine introduces inactivated meningococcal polysaccharides and diphtheria toxoid to the body. This triggers an immune response, including B-cell activation and antibody production, resulting in immunological memory against future exposure to these pathogens.

**Pharmacokinetics:** The vaccine is administered intramuscularly (IM). The conjugated polysaccharides are presented to antigen-presenting cells, leading to T-cell-dependent immune responses. The exact metabolic pathways and elimination routes are not fully defined, but it's assumed that the vaccine components are processed and cleared like other protein-polysaccharide conjugates.

**Mode of action:** The vaccine triggers T-cell-dependent B-cell activation, leading to IgG antibody production. The antibodies bind to the bacterial surface, promoting complement-mediated bacteriolysis and opsonophagocytosis, thereby eliminating the pathogens.  Diphtheria toxoid induces antibodies that neutralize the diphtheria toxin.

## **Dosage**


### **Standard Dosage**

#### **Adults (≥2 years):**
A single 0.5 mL dose IM.  A booster dose may be recommended for individuals at continued risk, typically at least 4 years after the previous dose.

#### **Children:**
* **2-23 months:**  Two 0.5 mL doses IM, 3 months apart (Menactra), or a four-dose series at 2, 4, 6 and 12 months of age (Menveo). For children aged 2 through 5 years at continued high risk of meningococcal disease, a second dose (0.5 mL) may be administered 2 months after the first dose.

* **9-23 months:** Two 0.5 mL doses IM, three months apart (Menactra).

* **≥2 years:** Single 0.5 mL dose IM.


#### **Special Cases:**
* **Elderly Patients:**  Standard adult dose applies (up to 55 years of age for some formulations).  Data on safety and efficacy beyond this age are limited.

* **Patients with Renal Impairment:** No specific dosage adjustments are indicated.

* **Patients with Hepatic Dysfunction:** No specific dosage adjustments are indicated.

* **Patients with Comorbid Conditions:** Consider individual patient factors and potential interactions.

### **Clinical Use Cases**

Dosage recommendations for specific clinical situations generally follow the standard dosage guidelines outlined above.

### **Dosage Adjustments**

Dose modifications are not typically required based on renal/hepatic function, metabolic disorders, or genetic polymorphisms.


## **Side Effects**


### **Common Side Effects**

Injection site reactions (pain, redness, swelling), headache, fatigue, muscle aches, chills, diarrhea, loss of appetite, irritability, drowsiness.


### **Rare but Serious Side Effects**

Severe allergic reactions (anaphylaxis), Guillain-Barré Syndrome (GBS), seizures, persistent high fever.


### **Long-Term Effects**

No long-term adverse effects specifically associated with this vaccine are known.

### **Adverse Drug Reactions (ADR)**

Anaphylaxis, GBS, seizures.


## **Contraindications**

History of severe allergic reaction to any vaccine component (including diphtheria toxoid), or to a previous dose of any meningococcal vaccine.


## **Drug Interactions**

Immunosuppressants may reduce the immune response to the vaccine. Concurrent administration with some vaccines (e.g., Tdap, PCV7) may affect antibody responses.


## **Pregnancy and Breastfeeding**

The vaccine's safety during pregnancy and breastfeeding hasn't been fully established. It's generally recommended only when the benefits clearly outweigh the risks. Consult shared decision-making with the patient concerning potential maternal benefits and fetal or neonatal risks, especially regarding MenB vaccines.


## **Drug Profile Summary**

* **Mechanism of Action:** Stimulates antibody production against *N. meningitidis* serogroups A, C, Y, W-135 and diphtheria toxoid.
* **Side Effects:** Injection site reactions, headache, fatigue, allergic reactions.
* **Contraindications:** Severe allergy to vaccine components.
* **Drug Interactions:** Immunosuppressants, certain vaccines.
* **Pregnancy & Breastfeeding:** Use with caution, if benefits outweigh risks.
* **Dosage:** See detailed section above.
* **Monitoring Parameters:** Observe for allergic reactions, monitor injection site.


## **Popular Combinations**

Often administered with other routine vaccines as per recommended immunization schedules.


## **Precautions**

Screen for contraindications and precautions (e.g., history of GBS).  Ensure access to appropriate medical treatment for potential allergic reactions. Follow standard injection protocols to minimize the risk of syncope.


## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Diphtheria Toxoid + Meningococcal Vaccine?**

**A:**  See dosage section for details, which vary by age and specific vaccine product.

### **Q2: Can this vaccine be given to immunocompromised patients?**

**A:** Yes, but the immune response might be suboptimal, and additional doses or alternative strategies may be necessary.

### **Q3: Does this vaccine protect against all types of meningitis?**

**A:** No, it targets specific *N. meningitidis* serogroups (A, C, Y, W-135) and diphtheria, not other causes of meningitis (e.g., serogroup B, viral meningitis).

### **Q4:  What are the most common side effects?**

**A:** The most common side effects are injection site reactions (pain, redness, swelling), headache, fatigue, and low-grade fever.

### **Q5: Are there any contraindications to this vaccine?**

**A:** A history of severe allergic reaction to any vaccine component, including diphtheria toxoid, is a contraindication.

### **Q6: Can this vaccine be administered during pregnancy or breastfeeding?**

**A:**  Safety during pregnancy and breastfeeding has not been fully established. Administer only if benefits clearly outweigh potential risks and discuss all options with the patient.  

### **Q7: Can this vaccine be given with other vaccines?**

**A:** Yes, but concurrent administration with certain vaccines may alter the immune response. Consult relevant guidelines and package inserts for specific recommendations.

### **Q8: What should be done if a patient experiences a mild allergic reaction after vaccination?**

**A:**  Mild reactions (e.g., localized hives) can often be managed with antihistamines. Observe the patient and provide appropriate medical care as needed.

### **Q9: How long does immunity last after vaccination?**

**A:**  Immunity wanes over time.  Booster doses are recommended for individuals at continued risk, generally after several years.

### **Q10:  Is a prior history of GBS a contraindication to this vaccine?**

**A:**  While GBS has been reported following meningococcal vaccination, it is not considered an absolute contraindication. Assess the individual patient's risk-benefit ratio.



